[HTML][HTML] A COVID-19 vaccine candidate using SpyCatcher multimerization of the SARS-CoV-2 spike protein receptor-binding domain induces potent neutralising …
…, P Hollinghurst, M Tully, K Moffat, C Chiu… - Nature …, 2021 - nature.com
There is need for effective and affordable vaccines against SARS-CoV-2 to tackle the
ongoing pandemic. In this study, we describe a protein nanoparticle vaccine against SARS-CoV-2. …
ongoing pandemic. In this study, we describe a protein nanoparticle vaccine against SARS-CoV-2. …
[HTML][HTML] Evaluation of the immunogenicity of prime-boost vaccination with the replication-deficient viral vectored COVID-19 vaccine candidate ChAdOx1 nCoV-19
…, K Moffat, H Sharpe, E Allen, V Mioulet, C Chiu… - NPJ vaccines, 2020 - nature.com
Clinical development of the COVID-19 vaccine candidate ChAdOx1 nCoV-19, a replication-deficient
simian adenoviral vector expressing the full-length SARS-CoV-2 spike (S) protein …
simian adenoviral vector expressing the full-length SARS-CoV-2 spike (S) protein …
[HTML][HTML] The SARS-CoV-2 Spike protein has a broad tropism for mammalian ACE2 proteins
…, M Varga, C Tsirigoti, M Tully, C Chiu… - PLoS …, 2020 - journals.plos.org
SARS Coronavirus 2 (SARS-CoV-2) emerged in late 2019, leading to the Coronavirus Disease
2019 (COVID-19) pandemic that continues to cause significant global mortality in human …
2019 (COVID-19) pandemic that continues to cause significant global mortality in human …
Inflammatory profiles across the spectrum of disease reveal a distinct role for GM-CSF in severe COVID-19
While it is now widely accepted that host inflammatory responses contribute to lung injury,
the pathways that drive severity and distinguish coronavirus disease 2019 (COVID-19) from …
the pathways that drive severity and distinguish coronavirus disease 2019 (COVID-19) from …
[HTML][HTML] Safety, tolerability and viral kinetics during SARS-CoV-2 human challenge in young adults
…, G Rapeport, WS Barclay, AP Catchpole, C Chiu - Nature Medicine, 2022 - nature.com
Since its emergence in 2019, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
has caused hundreds of millions of cases and continues to circulate globally. To establish …
has caused hundreds of millions of cases and continues to circulate globally. To establish …
[HTML][HTML] Daratumumab, lenalidomide, and dexamethasone for multiple myeloma
…, NZ Khokhar, L O'Rourke, C Chiu… - … England Journal of …, 2016 - Mass Medical Soc
Background Daratumumab showed promising efficacy alone and with lenalidomide and
dexamethasone in a phase 1–2 study involving patients with relapsed or refractory multiple …
dexamethasone in a phase 1–2 study involving patients with relapsed or refractory multiple …
Requirement for B cell linker protein (BLNK) in B cell development
R Pappu, AM Cheng, B Li, Q Gong, C Chiu, N Griffin… - Science, 1999 - science.org
Linker proteins function as molecular scaffolds to localize enzymes with substrates. In B cells,
B cell linker protein (BLNK) links the B cell receptor (BCR)–activated Syk kinase to the …
B cell linker protein (BLNK) links the B cell receptor (BCR)–activated Syk kinase to the …
[HTML][HTML] Daratumumab plus lenalidomide and dexamethasone for untreated myeloma
…, L Frenzel, X Leleu, T Ahmadi, C Chiu… - … England Journal of …, 2019 - Mass Medical Soc
Background Lenalidomide plus dexamethasone is a standard treatment for patients with newly
diagnosed multiple myeloma who are ineligible for autologous stem-cell transplantation. …
diagnosed multiple myeloma who are ineligible for autologous stem-cell transplantation. …
Infiltrating neutrophils mediate the initial angiogenic switch in a mouse model of multistage carcinogenesis
Matrix metalloprotease type 9 (MMP-9) has been functionally implicated in VEGF activation,
the induction and maintenance of chronic angiogenesis, and early stage tumor growth in a …
the induction and maintenance of chronic angiogenesis, and early stage tumor growth in a …
[HTML][HTML] Daratumumab plus bortezomib, melphalan, and prednisone for untreated myeloma
Background The combination of bortezomib, melphalan, and prednisone is a standard
treatment for patients with newly diagnosed multiple myeloma who are ineligible for autologous …
treatment for patients with newly diagnosed multiple myeloma who are ineligible for autologous …